Advertisement

18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Patients with Non-tuberculous Mycobacterial Infections

Published:March 17, 2023DOI:https://doi.org/10.1016/j.jinf.2023.03.013
      Dear editor,

      Abbreviations:

      TB (Tuberculosis), NTM (non-tuberculous, mycobacteria), NTM-LD (non-tuberculous, mycobacteria, lung, disease), PET/FDG, RGM (rapidly, growing, mycobacteria), SGM (slowly, growing, mycobacteria), SUV (standardized, uptake, value), CF (cystic, fibrosis)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yang J.
        • Kong J.
        • Li B.
        • Ji Z.
        • et al.
        Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
        J Infect. 2023 Feb 14; S0163-4453 (00087-00087) (Epub ahead of print)https://doi.org/10.1016/j.jinf.2023.02.019
        • Cowman S.
        • van Ingen J.
        • Griffith D.E.
        • Loebinger M.R.
        Non-tuberculous mycobacterial pulmonary disease.
        Eur Respir J. 2019; 54: 1900250https://doi.org/10.1183/13993003.00250-2019
      1. Daley C.L. , Iaccarino J.M. , Lange C. , et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020 ;71(4):e1-e36. doi:10.1093/cid/ciaa241

        • Lipman M.
        • Cleverley J.
        • Fardon T.
        • et al.
        Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK.
        BMJ Open Respir Res. 2020; 7e000591https://doi.org/10.1136/bmjresp-2020-000591
        • Kung B.T.
        • Seraj S.M.
        • Zadeh M.Z.
        • et al.
        An update on the role of 18F-FDG-PET/CT in major infectious and inflammatory diseases.
        Am J Nucl Med Mol Imaging. 2019 Dec 15; 9 (19): 255-273
        • Sánchez-Montalvá A.
        • Barios M.
        • Salvador F.
        • et al.
        Chiaravalloti A. Usefulness of FDG PET/CT in the management of tuberculosis. 14. PLOS ONE, 2019e0221516https://doi.org/10.1371/journal.pone.0221516
        • Aliberti S.
        • Codecasa L.R.
        • Gori A.
        • et al.
        IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol.
        Multidiscip Respir Med. 2018 Aug 9; 13: 33https://doi.org/10.1186/s40248-018-0141-8
      2. Del Giudice G. , Bianco A. , Cennamo A. , et al. Lung and Nodal Involvement in Nontuberculous Mycobacterial Disease: PET/CT Role. BioMed Res Int. 2015 ;2015:1-8. doi:10.1155/2015/353202

        • Demura Y.
        • Tsuchida T.
        • Uesaka D.
        • et al.
        Usefulness of 18F-fluorodeoxyglucose positron emissiontomography for diagnosing disease activity and monitoring therapeutic response in patients withpulmonary mycobacteriosis.
        Eur J Nucl Med Mol Imaging. 2009; 36: 632-639https://doi.org/10.1007/s00259-008-1009-5
        • Yan Q.
        • Wang W.
        • Zhao W.
        Differentiating nontuberculous mycobacterium pulmonary disease from pulmonary tuberculosis through the analysis of the cavity features in CT images using radiomics.
        BMC Pulm Med. 2022 Jan 7; 22: 4https://doi.org/10.1186/s12890-021-01766-2